Clinical trial

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

NCT00743938

Study summary

ClinicalTrials.gov

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention BMS-690514 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinib View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2009-03-01

PhasePHASE2

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

BMS-690514DRUG

ErlotinibDRUG · verified · RxNorm: erlotinib

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Mapped research locations

SeoulSouth Korea2 TaipeiTaiwan2 New YorkNew York, United States1 BostonMassachusetts, United States1 MadridSpain1 BarcelonaSpain1 PortlandOregon, United States1 MontrealQuebec, Canada1 DetroitMichigan, United States1 New HavenConnecticut, United States1 Winston-SalemNorth Carolina, United States1 ToulouseFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00743938 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.